AnaptysBio Announces 2026 Annual Meeting Results; Equity Plan Amended

What Happened
AnaptysBio, Inc. filed an 8-K reporting the results of its August 11, 2026 Annual Meeting of Stockholders. The company elected two Class III directors—Hollings Renton and John P. Schmid—to three-year terms, ratified KPMG LLP as its independent registered public accounting firm for the fiscal year ending June 30, 2027, received non-binding shareholder approval of named executive officer compensation, and approved an amendment to its 2017 Equity Incentive Plan. Amendment No. 1 to the 2017 Equity Incentive Plan was filed as Exhibit 10.1 to the 8-K.

Key Details

• Director elections: Hollings Renton — 15,304,522 votes For; 6,613,642 Withheld/Abstaining; 2,084,465 broker non-votes. John P. Schmid — 20,314,669 For; 1,603,495 Withheld/Abstaining; 2,084,465 broker non-votes.
• Auditor ratification: KPMG LLP ratified — 22,343,352 For; 1,640,401 Against; 18,876 Withheld/Abstaining.
• Executive compensation (advisory): 21,274,791 For; 609,979 Against; 33,394 Withheld/Abstaining; 2,084,465 broker non-votes.
• Equity plan amendment: Approved — 15,563,882 For; 6,332,813 Against; 21,469 Withheld/Abstaining; 2,084,465 broker non-votes. Amendment No. 1 to the Amended & Restated 2017 Equity Incentive Plan is attached as an exhibit.

Why It Matters
The vote confirms the company’s board composition for the coming term and keeps KPMG as the auditor, providing continuity on governance and financial reporting oversight. The non-binding advisory vote on executive pay passed, which signals shareholder acceptance but does not change compensation rules by itself. Approval of the amendment to the Equity Incentive Plan is material for investors because it governs stock-based awards (potential dilution and future executive/employee incentives); investors who track share-based compensation should review the filed amendment (Exhibit 10.1) for details.